Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cicatricial pemphigoid--a therapeutic problem]

M Axt1, S Wever, G Baier

  • 1Universitäts-Hautklinik, Würzburg.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|September 1, 1995
PubMed
Summary

Cicatricial pemphigoid, an autoimmune blistering disease, can be diagnosed via immunofluorescence. Direct immunofluorescence detecting IgA deposits may predict ocular involvement and guide treatment for this rare condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Mast cell-deficient mice <i>Mcpt5Cre/Dicer</i> <sup></sup> redefine the role of mast cells in experimental bullous pemphigoid.

Skin health and disease·2022
Same author

Annular plaques on the back.

Clinical and experimental dermatology·2022
Same author

COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.

The British journal of dermatology·2021
Same author

European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Area of Science:

  • Immunodermatology
  • Autoimmune Blistering Diseases

Background:

  • Cicatricial pemphigoid is a rare autoimmune subepidermal blistering disease affecting skin and mucous membranes.
  • Early diagnosis and prognostic indicators are crucial for effective management.

Observation:

  • Eight patients (average age 69) with clinically diagnosed cicatricial pemphigoid were studied.
  • Initial symptoms varied, including oral erosions, skin blisters, and ocular involvement.
  • Direct immunofluorescence confirmed diagnoses and revealed IgA deposits in patients with ocular disease.

Findings:

  • Circulating IgG antibodies targeting a 230-kD epidermal protein were identified in one patient via immunoblotting.
  • Direct immunofluorescence detected IgA deposits in four of five patients with significant ocular involvement.

Related Experiment Videos

  • IgA deposits identified pre-clinically may serve as a prognostic marker for ocular complications.

    • Implications:

    • Direct immunofluorescence findings, particularly IgA deposits, can aid in predicting cicatricial pemphigoid progression and guiding therapeutic strategies.
    • While dexamethasone-cyclophosphamide pulse therapy and dapsone showed efficacy for mucocutaneous lesions, ocular involvement remained challenging.
    • Further research into cicatricial pemphigoid pathogenesis and treatment is warranted.